Stereotaxis, Inc. (STXS)

Market Cap	144.09M
Revenue (ttm)	28.15M
Net Income (ttm)	-19.64M
Shares Out	75.05M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,811
Open	1.90
Previous Close	1.87
Day's Range	1.87 - 1.94
52-Week Range	1.55 - 3.81
Beta	1.70
Analysts	Buy
Price Target	5.61 (+190.67%)
Earnings Date	May 9, 2023

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to ma...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 12, 2004
• Employees: 130
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: STXS

Financial Performance

In 2022, Stereotaxis's revenue was $28.15 million, a decrease of -19.63% compared to the previous year's $35.02 million. Losses were -$19.64 million, 62.8% more than in 2021.

Analyst Forecast

According to 14 analysts, the average rating for STXS stock is "Buy." The 12-month stock price forecast is $5.61, which is an increase of 190.67% from the latest price.

Price Target

$5.61

(190.67% upside)

Analyst Consensus: Buy